RT Journal Article
SR Electronic
T1 Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1053
OP 1058
DO 10.3899/jrheum.181123
VO 46
IS 8
A1 Kathleen M. Andersen
A1 Jonathan T.L. Cheah
A1 Lyn March
A1 Susan J. Bartlett
A1 Dorcas Beaton
A1 Clifton O. Bingham III
A1 Peter M. Brooks
A1 Robin Christensen
A1 Philip G. Conaghan
A1 Maria-Antonietta D’Agostino
A1 Maarten de Wit
A1 Amylou C. Dueck
A1 Susan M. Goodman
A1 Shawna Grosskleg
A1 Catherine L. Hill
A1 Martin Howell
A1 Sarah L. Mackie
A1 Bethan Richards
A1 Beverly Shea
A1 Jasvinder A. Singh
A1 Vibeke Strand
A1 Peter Tugwell
A1 George A. Wells
A1 Lee S. Simon
YR 2019
UL http://www.jrheum.org/content/46/8/1053.abstract
AB Objective. Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.Methods. Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.Results. Five themes pertaining to drug safety measurement emerged.Conclusion. Current approaches have failed to include data from the patient’s perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.